celecoxib and 2,3-dinor-6-ketoprostaglandin f1alpha

celecoxib has been researched along with 2,3-dinor-6-ketoprostaglandin f1alpha in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (25.00)	18.2507
2000's	2 (50.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Catella-Lawson, F; FitzGerald, GA; Kapoor, S; Lawson, JA; Mardini, IA; McAdam, BF	1
Frölich, JC; Gutzki, FM; Marhauer, V; Stichtenoth, DO; Tsikas, D	1
Gertz, BJ; Gottesdiener, KM; Hilliard, DA; Hreniuk, D; Lasseter, KC; Miller, J; Schwartz, JI; Snyder, KM; Thach, C	1
Alamuddin, N; Cen, L; Fitzgerald, GA; Lawson, JA; Propert, KJ; Skarke, C	1

Trials

3 trial(s) available for celecoxib and 2,3-dinor-6-ketoprostaglandin f1alpha

Article	Year
Effects of specific COX-2-inhibition on renin release and renal and systemic prostanoid synthesis in healthy volunteers. Kidney international, 2005, Volume: 68, Issue:5 Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aldosterone; Body Weight; Celecoxib; Creatinine; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Diuretics; Female; Furosemide; Humans; Indomethacin; Kidney; Potassium; Prostaglandins; Pyrazoles; Renin; Sodium; Sulfonamides; Thromboxane B2	2005
Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet. Journal of clinical pharmacology, 2007, Volume: 47, Issue:12 Topics: 6-Ketoprostaglandin F1 alpha; Administration, Oral; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Body Weight; Celecoxib; Constipation; Creatinine; Diarrhea; Dose-Response Relationship, Drug; Double-Blind Method; Electrolytes; Etoricoxib; Female; Headache; Humans; Male; Middle Aged; Naproxen; Potassium; Prostaglandins; Pyrazoles; Pyridines; Sodium; Sulfonamides; Sulfones; Thromboxane B2	2007
Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649. Clinical pharmacology and therapeutics, 2012, Volume: 91, Issue:6 Topics: 6-Ketoprostaglandin F1 alpha; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Asian; Black People; Carbonic Anhydrase Inhibitors; Cardiovascular Diseases; Celecoxib; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Epoprostenol; Female; Furans; Humans; Male; Middle Aged; Prostaglandin Antagonists; Prostaglandins; Pyrazoles; Risk Assessment; Sulfonamides; Thromboxane B2; White People; Young Adult	2012

Other Studies

1 other study(ies) available for celecoxib and 2,3-dinor-6-ketoprostaglandin f1alpha

Article	Year
Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proceedings of the National Academy of Sciences of the United States of America, 1999, Jan-05, Volume: 96, Issue:1 Topics: 6-Ketoprostaglandin F1 alpha; Adult; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Epoprostenol; Female; Humans; Ibuprofen; Isoenzymes; Male; Membrane Proteins; Middle Aged; Monocytes; Platelet Aggregation; Platelet Aggregation Inhibitors; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Thromboxane B2	1999

Article

Year

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.

Proceedings of the National Academy of Sciences of the United States of America, 1999, Jan-05, Volume: 96, Issue:1

Topics: 6-Ketoprostaglandin F1 alpha; Adult; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Epoprostenol; Female; Humans; Ibuprofen; Isoenzymes; Male; Membrane Proteins; Middle Aged; Monocytes; Platelet Aggregation; Platelet Aggregation Inhibitors; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Thromboxane B2

1999